2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Pembrolizumab (anti-PD-1)

Pembrolizumab (anti-PD-1)  (Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1))

Cat. No.: HY-P9902A Purity: 99.90%
COA
SDS
Technical Support

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

For research use only. We do not sell to patients.

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Pembrolizumab (anti-PD-1) Featured Recommendations:

Pembrolizumab (anti-PD-1) Related Antibodies

Top Publications Citing Use of Products

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Aug 16;31(1):278.  [Abstract]

    Scratch assay comparing the migration ability of MDA-MB-231/PEM and MDA-MB-231 cells treated with 10 µg/mL Pembrolizumab (PEM).

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 12;13(1):4032.  [Abstract]

    PD-L1/PD-1 binding activity assay after treatment with free aPD-L1 (Pembrolizumab) or SPIND2 (40 µg/mL) with or without US irradiation.

    Pembrolizumab (anti-PD-1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jul 12;13(1):4032.  [Abstract]

    Relative tumor volumes of primary tumors of Panc02 tumor-bearing C57BL/6 mice (n = 6) after systemic injection of saline, free-drug mixture (on day 0, 3, and 6, 4 mg/kg body weight for NLG919 and aPD-L1(Pembrolizumab)), or SPIND2 (0.2 mL, 0.6 mg/mL) with or without US irradiation.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1[1][2].

    Isotype

    Human IgG4 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    PDCD1/PD-1/CD279
    In Vitro

    Deferoxamine (Df) chelates pembrolizumab and does not block or alter the binding affinity or specificity of pembrolizumab to CD4+ and CD8+ T cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Pembrolizumab (anti-PD-1) Related Antibodies
    In Vivo

    Experiments confirmed that 89Zr-Df-Pembrolizumab has a specific activity of 740 mBq/mg antibody. mBq is the unit of radioactivity, used to measure radioactive decay[2].
    Positron emitter 89Zr-labeled deferoxamine (Df)-Pembrolizumab, through PET imaging, its biodistribution has be dynamically tracked. The results shows that pembrolizumab remained stable in the blood circulation and accumulated most in liver and spleen tissues. And it shows similar biodistribution and pharmacokinetics in mice and rat[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Gene ID

    5133  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    146.341 kDa

    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Pembrolizumab (anti-PD-1)]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 kappa
    Biological Activity
    • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    Purity & Documentation

    Purity: 99.90%

    SDS (251 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Pembrolizumab (anti-PD-1) Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Pembrolizumab (anti-PD-1)MK-3475 (anti-PD-1) Lambrolizumab (anti-PD-1)PD-1/PD-L1PD-1/Programmed death-ligand 189Zrdosimetrypembrolizumabpositron emission tomographyPETInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Pembrolizumab (anti-PD-1)
    Cat. No.:
    HY-P9902A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.